GlassScriptPhysician profile
Joseph Schulman
NPI 1992745061
$11,518.21
in general payments reported to CMS, 2019-2025
60 companies · $1,308 in 2025
The $1,308 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,595 · 2020: $917 · 2021: $2,048 · 2022: $1,940 · 2023: $2,123 · 2024: $1,586 · 2025: $1,308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,982 · Education: $35.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,981.90 |
| Education | $35.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,075.82 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $917.52 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $853.61 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $649.61 | 2021-2025 | |
| Glaxosmithkline, LLC. | $553.20 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Corcept Therapeutics | $514.07 | 2023-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $475.01 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Otsuka America Pharmaceutical, INC. | $408.75 | 2021-2025 | Rexulti, Nuedexta, Jynarque |
| Janssen Pharmaceuticals, INC | $348.80 | 2019-2023 | Xarelto |
| Pfizer INC. | $293.27 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $245.99 | 2019-2024 | |
| Almatica Pharma LLC | $220.91 | 2022-2023 | Loreev Xr, Gralise, Sertraline Hcl |
| Merck Sharp & Dohme LLC | $211.44 | 2019-2024 | Dificid |
| Astellas Pharma US INC | $191.90 | 2019-2025 | Veozah, Myrbetriq |
| Kowa Pharmaceuticals America, INC. | $189.94 | 2019-2022 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $188.81 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $188.08 | 2019-2024 | Ztlido |
| Amgen INC. | $178.21 | 2020-2025 | Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $169.59 | 2019-2023 | |
| Teleflex LLC | $164.97 | 2023 | Urolift |
| Abbott Laboratories | $161.82 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Avanir Pharmaceuticals, INC. | $154.82 | 2019-2021 | |
| Allergan, INC. | $151.15 | 2019-2020 | |
| Exact Sciences Corporation | $143.44 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Eisai INC. | $139.15 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.42 | 2019-2023 | Jardiance |
| Idorsia Pharmaceuticals US INC | $125.70 | 2023-2024 | Quviviq |
| Dexcom, INC. | $122.85 | 2021-2024 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $120.67 | 2020-2025 | Contrave |
| Daiichi Sankyo INC. | $118.50 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $112.30 | 2022-2023 | Hetlioz |
| Bausch Health US, LLC | $84.57 | 2020-2023 | Aplenzin |
| Paratek Pharmaceuticals, INC. | $82.18 | 2024-2025 | Nuzyra, Xhance |
| Ucb, INC. | $76.88 | 2021-2023 | Briviact |
| Teva Pharmaceuticals USA, INC. | $70.04 | 2019-2020 | |
| Amarin Pharma, INC. | $66.97 | 2021-2023 | |
| Biogen, INC. | $53.16 | 2021-2022 | |
| Lundbeck LLC | $49.47 | 2023-2024 | Rexulti |
| Sumitomo Pharma America, INC. | $48.80 | 2023 | Gemtesa |
| Arbor Pharmaceuticals, INC. | $43.10 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.75 | 2019-2023 | Trulance, Xifaxan |
| Xeris Pharmaceuticals, INC. | $35.39 | 2025 | Recorlev |
| Biohaven Pharmaceutical Holding Company LTD. | $34.98 | 2022 | |
| Neurelis, INC. | $29.73 | 2022-2023 | Valtoco |
| Sun Pharmaceutical Industries INC. | $28.47 | 2019-2021 | |
| Baxter Healthcare | $26.75 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Shield Therapeutics INC | $25.47 | 2025 | |
| Acadia Pharmaceuticals INC | $24.99 | 2021 | |
| Acorda Therapeutics, INC | $24.93 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.52 | 2021 | |
| Seqirus USA INC | $14.94 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $14.66 | 2019 | |
| Acella Pharmaceuticals, LLC | $14.33 | 2024 | NP Thyroid 60 |
| Alnylam Pharmaceuticals INC. | $14.07 | 2022 | |
| Alexion Pharmaceuticals, INC. | $14.01 | 2021 | |
| Phadia US INC. | $13.60 | 2024 | Immunocap |
| Medicure Pharma INC. | $13.54 | 2025 | Zypitamag |
| Cmp Pharma, INC. | $13.32 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $12.60 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Schulman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.